These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1498952)

  • 21. Behavioral implications of dopaminergic neurons in the mesolimbic system.
    Iversen SD; Koob GF
    Adv Biochem Psychopharmacol; 1977; 16():209-14. PubMed ID: 560790
    [No Abstract]   [Full Text] [Related]  

  • 22. Mesolimbic dopamine in obesity and diabetes.
    Gainetdinov RR
    Am J Physiol Regul Integr Comp Physiol; 2007 Aug; 293(2):R601-2. PubMed ID: 17596319
    [No Abstract]   [Full Text] [Related]  

  • 23. The endocannabinoid system and nondrug rewarding behaviours.
    Fattore L; Melis M; Fadda P; Pistis M; Fratta W
    Exp Neurol; 2010 Jul; 224(1):23-36. PubMed ID: 20353776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesolimbic dopamine activation--the key to nicotine reinforcement?
    Clarke PB
    Ciba Found Symp; 1990; 152():153-62; discussion 162-8. PubMed ID: 2209252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GABAergic and enkephalinergic regulation of locomotion in the ventral pallidum: involvement of the mesolimbic dopamine system.
    Kalivas PW; Klitenick MA; Hagler H; Austin MC
    Adv Exp Med Biol; 1991; 295():315-26. PubMed ID: 1776575
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulatory behaviour, exploration and locomotion following NMDA or 6-OHDA lesions in the rat nucleus accumbens.
    Weissenborn R; Winn P
    Behav Brain Res; 1992 Nov; 51(2):127-37. PubMed ID: 1466779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lesions of the mesolimbic dopamine system disrupt signalled escape responses in the rat.
    Wilson WJ; Hall JC
    Acta Neurobiol Exp (Wars); 1988; 48(2-3):117-21. PubMed ID: 3421151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of mesolimbic dopaminergic behaviors by cholecystokinin.
    Crawley JN
    Ann N Y Acad Sci; 1988; 537():380-96. PubMed ID: 3059933
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1980; 69(3):227-33. PubMed ID: 6774362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fluorescence of dopaminergic terminals during elaboration of alimentary conditioned reflexes in the cat].
    Zhukova EM; Nikiforov AF; Spiridonov VK
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1984; 34(4):738-42. PubMed ID: 6495858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system.
    Spyraki C; Fibiger HC; Phillips AG
    Psychopharmacology (Berl); 1983; 79(2-3):278-83. PubMed ID: 6405439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lesions of the superior colliculus in the rat differentiate between nigrostriatal and mesolimbic dopamine systems.
    Dawbarn D; Pycock CJ
    Brain Res; 1982 Mar; 235(1):148-55. PubMed ID: 6892367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of lesion of mesolimbic dopamine neurons on pain threshold and morphine analgesia in rats.
    Szreniawski Z; Mészáros J; Gajewska S; Tarchalska-Kryńska B
    Pol J Pharmacol Pharm; 1977; 29(5):521-5. PubMed ID: 22847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CART peptides: modulators of mesolimbic dopamine, feeding, and stress.
    Dominguez G; Vicentic A; Del Giudice EM; Jaworski J; Hunter RG; Kuhar MJ
    Ann N Y Acad Sci; 2004 Oct; 1025():363-9. PubMed ID: 15542737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies.
    Mylecharane EJ
    Behav Brain Res; 1996; 73(1-2):1-5. PubMed ID: 8788468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rolling the dice: the importance of mesolimbic dopamine signaling in risky decision making.
    Sugam JA; Carelli RM
    Neuropsychopharmacology; 2013 Jan; 38(1):248. PubMed ID: 23147490
    [No Abstract]   [Full Text] [Related]  

  • 37. Substance P modulation of the mesolimbic dopamine system.
    Kalivas P
    Prog Clin Biol Res; 1985; 192():403-8. PubMed ID: 2417255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine.
    Swerdlow NR; Mansbach RS; Geyer MA; Pulvirenti L; Koob GF; Braff DL
    Psychopharmacology (Berl); 1990; 100(3):413-6. PubMed ID: 2315438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between mesolimbic dopamine neurons, cholecystokinin, and neurotensin: evidence using in vivo voltammetry.
    Phillips AG; Blaha CD; Fibiger HC; Lane RF
    Ann N Y Acad Sci; 1988; 537():347-61. PubMed ID: 3059931
    [No Abstract]   [Full Text] [Related]  

  • 40. A role for the mesolimbic dopamine system in the reinforcing properties of diazepam.
    Spyraki C; Fibiger HC
    Psychopharmacology (Berl); 1988; 94(1):133-7. PubMed ID: 3126522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.